GleamWall
中文EN

AVIR Atea Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1593899 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-5.7%
TTM EPS YoY-10.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-63.2%
ROA-57.2%
ROIC (approx.)-86.0%
Asset turnover—

Leverage & solvency

Liabilities / assets12.5%
Debt / equity0.00x
Current ratio8.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$148.02M$144.10M
SG&A expense$32.86M$48.85M
Operating income-$180.89M-$192.95M
Pretax income-$164.51M-$167.46M
Income tax-$6.16M$925,000
Net income-$158.35M-$168.38M
EBITDA-$180.47M-$192.53M
EPS (basic)-1.94-2.00
EPS (diluted)-1.94-2.00
Weighted avg. shares (diluted)81.50M84.26M
Balance sheet
Cash & equivalents$95.71M$64.70M
Short-term investments$206.12M$390.02M
Current assets$310.99M$462.36M
PP&E, net$457,000$873,000
Total assets$315.22M$464.67M
Current liabilities$39.78M$18.60M
Total liabilities$39.78M$25.80M
Shareholders' equity$275.43M$438.87M
Shares outstanding78.13M84.46M
Cash flow statement
Operating cash flow-$132.03M-$135.50M
Investing cash flow$188.79M$56.10M
Financing cash flow-$25.75M$267,000
Depreciation & amortization$416,000$416,000
Stock-based compensation$20.72M$51.77M
Share buybacks$25.52M$0

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.